Pentoxifylline-d6 is intended for use as an internal standard for the quantification of pentoxifylline by GC- or LC-MS. Pentoxifylline is a hemorrheologic agent.1 It increases the deformability of washed isolated human erythrocytes when used at a concentration of 100 μM.2 Pentoxifylline (1, 2, and 3 mM) inhibits ADP-induced platelet aggregation in isolated human whole blood.3 It inhibits thrombus formation induced by ADP in a hamster cheek pouch model when administered at doses of 5, 10, and 20 mg/kg.4 Formulations containing pentoxifylline have been used in the treatment of intermittent claudication.
1.Ward, A., and Clissold, S.P.Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacyDrugs34(1)50-97(1987)
2.S?oczyńska, K., Kózka, M., P?kala, E., et al.In vitro effect of pentoxifylline and lisofylline on deformability and aggregation of red blood cells from healthy subjects and patients with chronic venous diseaseActa Biochim. Pol.60(1)129-135(2013)
3.Magnusson, B., Gunnarsson, M., Berntorp, E., et al.Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humansEur. J. Pharmacol.581(3)290-295(2008)
4.Michal, M., Giessinger, N., and Schr?er, R.Reduced thrombus formation in vivo after administration of pentoxifylline (Trental)Thromb. Res.56(3)359-368(1989)
